Found: 82
Select item for more details and to access through your institution.
An Open-label, Phase IV Study Evaluating Lidose-isotretinoin Administered without Food in Patients with Severe Recalcitrant Nodular Acne: Low Relapse Rates Observed Over the 104-week Post-treatment Period.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Update on the Management of Rosacea from the American Acne & Rosacea Society (AARS).
- Published in:
- 2019
- By:
- Publication type:
- journal article
The online acne market: analyzing ingredients and price of over-the-counter acne products.
- Published in:
- Archives of Dermatological Research, 2023, v. 315, n. 9, p. 2715, doi. 10.1007/s00403-023-02665-8
- By:
- Publication type:
- Article
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
- Published in:
- JAMA Dermatology, 2023, v. 159, n. 6, p. 613, doi. 10.1001/jamadermatol.2023.0846
- By:
- Publication type:
- Article
Isotretinoin Laboratory Monitoring in Acne Treatment: A Delphi Consensus Study.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Long-term Follow-up Study of Ingenol Mebutate Gel for the Treatment of Actinic Keratoses.
- Published in:
- JAMA Dermatology, 2013, v. 149, n. 6, p. 666, doi. 10.1001/jamadermatol.2013.2766
- By:
- Publication type:
- Article
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 3, p. 485, doi. 10.1007/s40257-024-00853-4
- By:
- Publication type:
- Article
Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 4, p. 595, doi. 10.1007/s40257-023-00792-6
- By:
- Publication type:
- Article
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet's Syndrome.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 5, p. 809, doi. 10.1007/s40257-023-00783-7
- By:
- Publication type:
- Article
Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 2, p. 305, doi. 10.1007/s40257-022-00739-3
- By:
- Publication type:
- Article
Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug.
- Published in:
- American Journal of Clinical Dermatology, 2022, v. 23, n. 1, p. 93, doi. 10.1007/s40257-021-00650-3
- By:
- Publication type:
- Article
Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice.
- Published in:
- American Journal of Clinical Dermatology, 2022, v. 23, n. 1, p. 69, doi. 10.1007/s40257-021-00643-2
- By:
- Publication type:
- Article
50 Years of Topical Retinoids for Acne: Evolution of Treatment.
- Published in:
- American Journal of Clinical Dermatology, 2021, v. 22, n. 3, p. 315, doi. 10.1007/s40257-021-00594-8
- By:
- Publication type:
- Article
Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups.
- Published in:
- American Journal of Clinical Dermatology, 2019, v. 20, n. 5, p. 711, doi. 10.1007/s40257-019-00450-w
- By:
- Publication type:
- Article
Moderate and Severe Inflammatory Acne Vulgaris Effectively Treated with Single-Agent Therapy by a New Fixed-Dose Combination Adapalene 0.3 %/Benzoyl Peroxide 2.5 % Gel: A Randomized, Double-Blind, Parallel-Group, Controlled Study.
- Published in:
- American Journal of Clinical Dermatology, 2016, v. 17, n. 3, p. 293, doi. 10.1007/s40257-016-0178-4
- By:
- Publication type:
- Article
Short Term and Long-Term Efficacy of Calcipotriene/ Betamethasone Dipropionate Foam Combination.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2022, v. 15, p. 809, doi. 10.2147/CCID.S361884
- By:
- Publication type:
- Article
Safety and efficacy of tazarotene foam for the treatment of acne vulgaris.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2013, v. 6, p. 123, doi. 10.2147/CCID.S34054
- By:
- Publication type:
- Article
Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2249, doi. 10.1007/s13555-024-01226-9
- By:
- Publication type:
- Article
Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 5, p. 1211, doi. 10.1007/s13555-024-01155-7
- By:
- Publication type:
- Article
Maintenance of Investigator's Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 4, p. 875, doi. 10.1007/s13555-024-01129-9
- By:
- Publication type:
- Article
Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 Trials.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 10, p. 2443, doi. 10.1007/s13555-023-01008-9
- By:
- Publication type:
- Article
Calcipotriene and Betamethasone Dipropionate PAD-Cream Demonstrates Greater Treatment Efficacy in Patients with Moderate-to-Severe Psoriasis Compared to Topical Suspension/Gel: A Subgroup Analysis of Two Phase 3 Studies.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 9, p. 2031, doi. 10.1007/s13555-023-00979-z
- By:
- Publication type:
- Article
Patient and Physician Perceptions of Psoriatic Disease in the United States: Results from the UPLIFT Survey.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 6, p. 1329, doi. 10.1007/s13555-023-00929-9
- By:
- Publication type:
- Article
Acne Scarring: Why We Should Act Sooner Rather Than Later.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 4, p. 1157, doi. 10.1007/s13555-021-00560-6
- By:
- Publication type:
- Article
Why We Should Consider Evidence-Based Treatment Options for Truncal Acne.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Why Topical Retinoids Are Mainstay of Therapy for Acne.
- Published in:
- Dermatology & Therapy, 2017, v. 7, n. 3, p. 293, doi. 10.1007/s13555-017-0185-2
- By:
- Publication type:
- Article
Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam is Effective, Independent of Body Mass Index and the Extent and Severity of Psoriasis.
- Published in:
- 2016
- By:
- Publication type:
- Report
Microencapsulated Benzoyl Peroxide for Rosacea in Context: A Review of the Current Treatment Landscape.
- Published in:
- Drugs, 2024, v. 84, n. 3, p. 275, doi. 10.1007/s40265-024-02003-w
- By:
- Publication type:
- Article
734 - Efficacy and safety of upadacitinib vs dupliumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up).
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.107
- By:
- Publication type:
- Article
733 - Nemolizumab elicits fast itch response in atopic dermatitis within 2 days: a post hoc analysis of ARCADIA 1 and 2 data.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.106
- By:
- Publication type:
- Article
703 - Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with moderate and/or more extensive atopic dermatitis: subgroup analysis from the TRuE-AD3 study.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.077
- By:
- Publication type:
- Article
696 - Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.070
- By:
- Publication type:
- Article
684 - Amlitelimab (an anti-OX40 ligand antibody) vs placebo in patients with moderate-to-severe atopic dermatitis: study design of phase 3 OCEANA clinical trials COAST 1/2, SHORE, AQUA, and ESTUARY.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.058
- By:
- Publication type:
- Article
671 - Rapid and early onset of itch relief with tapinarof cream 1% once daily in two pivotal phase 3 trials in adults and children down to two years of age with atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.045
- By:
- Publication type:
- Article
669 - Characteristics of adult patients with atopic dermatitis initiating biologics and JAK inhibitors in the CorEvitas AD Registry.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.043
- By:
- Publication type:
- Article
640 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.021
- By:
- Publication type:
- Article
629 - A novel efficacy index for long-term therapy outcomes expressed by maintenance of EASI 75 and IGA 0,1 response in atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.013
- By:
- Publication type:
- Article
603 - Ruxolitinib cream 1.5% twice daily for the treatment of extensive atopic dermatitis in children aged 2–11 years: 52 week results from a maximum-use trial.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.003
- By:
- Publication type:
- Article
Conjunctivitis adverse events in dupilumab clinical trials.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii58, doi. 10.1093/bjd/ljad498.060
- By:
- Publication type:
- Article
Treatment efficacy in patients with moderate-to-severe atopic dermatitis who switched from dupilumab to abrocitinib in JADE EXTEND, a phase 3 long-term extension study.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii32, doi. 10.1093/bjd/ljad498.035
- By:
- Publication type:
- Article
Rapid and early onset of itch relief with tapinarof cream 1% once daily in two pivotal phase 3 trials in adults and children down to two years of age with atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii18, doi. 10.1093/bjd/ljad498.022
- By:
- Publication type:
- Article
Tapinarof cream 1% once daily: significant efficacy in the treatment of atopic dermatitis in two pivotal phase 3 trials in adults and children down to 2 years of age.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii17, doi. 10.1093/bjd/ljad498.021
- By:
- Publication type:
- Article
Efficacy and safety of upadacitinib through 140 weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii8, doi. 10.1093/bjd/ljad498.010
- By:
- Publication type:
- Article
Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii9, doi. 10.1093/bjd/ljad498.012
- By:
- Publication type:
- Article
380 Patients maintain stable response with no or minimal fluctuations during treatment with lebrikizumab up to Week 52.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.008
- By:
- Publication type:
- Article
382 Lebrikizumab provides clinically meaningful improvements in atopic dermatitis in patients previously treated with dupilumab.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.010
- By:
- Publication type:
- Article